de Sa Dantas Bezerra D, et al. - In this prospective, randomized, single-blind study, 21 participants were researched to assess the outcomes of 300 U vs 500 U of abobotulinumtoxinA (ABO) intravesical injections for the treatment of idiopathic overactive bladder (OAB) refractory to first and second-line treatments. They noted an increase in maximum cistometric capacity (MCC) from 185.0 to 270.9 mL (300 U) and from 240.8 to 311.7 mL (500 U) when comparing the baseline with 12 weeks. They noted dryness in 91% of cases in both groups at 12 weeks and return of episodes of incontinence in 50% (300 U) and 0% (500 U) at 24 weeks. They also recorded status of candidates as better or much better [patient global impression of improvement (PGI-I)] in 70% (300 U) and 88.9% (500 U) at 12 w; and 50% (300 U) and 100% (500 U), at 24 w.